Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 SUPPLEMENTARY MATERIALS Supplementary Table 1: Univariate analysis of factors affecting CR, CRc, ORR, and OS rates CR P CRc P ORR P OS P Rate Rate Rate Rate at 1 yr Therapeutic regimen mLDAC vs. DAC 46.8 % vs. 19.0% <0.01 50.6% vs. 23.8% <0.01 55.8% vs. 40.5% 0.16 44.2% vs. 40.7% 0.35 Age at diagnosis ≤70 yrs vs. >70 yrs 45.5% vs. 29.7% 0.11 49.1% vs. 34.4% 0.15 61.8% vs. 40.6% 0.04 55.5% vs. 32.5% <0. 




  UPN = unique patient number; ICTx. = intensive chemotherapy; OS = overall survival; MTZ = mitoxantrone; ARA = cytarabine; mLDAC = modified low-dose cytarabine; CLO = clofarabine, FLANG4 = granulocyte colony-stimulating factor (300 µg for 1 day) and fludarabine (30 mg/m 2 ) + cytarabine (1 g/m 2 ) + mitoxantrone (10 mg/m 2 ) for 4 days; VP = etoposide; IDA= idarubicin; BHAC = N 4 -behenoyl-1-β-D-arabinofuranosyl cytosine; NR = no response; NA = not available; CR = complete remission; CRp = complete remission without platelet recovery; CRi = incomplete complete remission; DAC = decitabine. * calculated from date of abbreviated ICTx. administration as a salvage treatment to any cause of death or last follow-up. 


Table 2 : Outcomes of patients who received mLDAC as a salvage treatment

 2 UPN = unique patient number; OS = overall survival; mLDAC = modified low-dose cytarabine; NR = no response; NA = not available; DAC = decitabine; CR = complete remission; PR = partial remission; CRi = incomplete complete remission * calculated from date of mLDAC administration as a salvage treatment to any cause of death or last follow-up. 


	ECGO PS score								
	<2/≥2	30.8% vs. 40.0%	0.44	33.3% vs. 45.0%	0.31	43.6% vs. 53.8%	0.40	38.8% vs. 44.7%	0.31
	HCT-CI								
	<3 vs. ≥3	41.6% vs. 28.6%	0.23	46.8% vs. 31.0%	0.14	55.8% vs. 40.5%	0.16	48.6% vs. 32.8%	0.05
	Disease etiology								
	De novo vs MRC or secondary	38.5% vs. 30.4%	0.63	42.7% vs. 34.8%	0.65	53.1% vs. 39.1%	0.33	45.2% vs. 34.2%	0.21
	WBC count								
	<10.0 × 10 9 /l vs ≥10.0 × 10 9 /l	36.5% vs. 37.5%	1.00	39.7% vs. 42.9%	0.87	52.4% vs. 48.2%	0.79	42.5% vs. 43.8%	0.28
	Hemoglobin								
	≤8.0 g/dl vs 8.0 g/dl	38.5% vs. 35.5%	0.87	40.4% vs 41.9%	1.00	49.1% vs. 51.6%	0.93	41.1% vs. 44.7%	0.91
	Platelet count								
	<50 × 10 9 /l vs 50 × 10 9 /l	40.3% vs. 33.3%	0.55	45.2% vs. 36.8%	0.46	53.2% vs. 47.4%	0.65	44.8% vs. 41.2%	0.95
	PB blast								
	<30% vs ≥30%	37.8% vs. 36.8%	1.00	43.5% vs. 38.6%	0.72	56.5% vs. 43.9%	0.23	45.6% vs. 40.3%	0.96
	BM blast								
	<30% vs ≥30%	50.0% vs. 35.2%	0.44	50.0% vs. 40%	0.67	64.3% vs. 48.6%	0.41	45.9% vs. 42.5%	0.99
	LDH								
	≤UNL/>UNL	36.0% vs. 37.2%	1.00	40.0% vs. 41.5%	1.00	44.0% vs. 52.1%	0.62	40.0% vs. 43.8%	0.58
	Cytogenetic risk								
	Favorable or Intermediate vs Adverse	38.2% vs. 29.4%	0.59	43.1% vs. 29.4%	0.43	52.0% vs. 41.2%	0.58	46.4% vs. 23.5%	0.10
	CR = complete remission; CRc = composite complete remission; ORR = overall response; OS = overall survival; mLDAC = modified low-dose cytarabine; DAC = decitabine;
	ECOG PS = the Eastern Cooperative Oncology Group performance statu; HCT-CI = the hematopoietic cell transplant co-morbidity index; MRC = myelodysplasia-related
	change; PB = peripheral blood; BM = bone marrow; LDH = lactate dehydrogenase; UNL = upper normal limit.			

Table 3 : Outcomes of patients who received abbreviated ICTx. as a salvage treatment

 3 
	UPN	Abbreviated ICTx. regimen	Group	Response Relapse	OS	OS duration *
	1	MTZ (6 mg/m 2 )/ARA (30 mg) 3/14	mLDAC	NR	NA	Dead	3.1 mo
	2	MTZ (6 mg/m 2 )/ARA (20 mg)/VP (100 mg) 3/14/14	mLDAC	NR	NA	Dead	3.1 mo
	3	MTZ (6 mg/m 2 )/ARA (40 mg)/VP (100 mg) 2/5/5	mLDAC	CR	No	Dead	40.1 mo
	4	IDA (12 mg/m 2 )/BHAC (300 mg/m 2 ) 3/5	mLDAC	NR	NA	Dead	3.2 mo
	5	IDA (12 mg/m 2 )/BHAC (300 mg/m 2 ) 3/5	mLDAC	CRp	Yes	Alive	79.2 mo
	6	IDA (12 mg/m 2 )/BHAC (300 mg/m 2 ) 3/5	mLDAC	CRi	Yes	Dead	21.6 mo
	7	IDA (12 mg/m 2 )/BHAC (300 mg/m 2 ) 3/5	mLDAC	NR	NA	Dead	1.1 mo
	8	CLO (40 mg/m 2 )/ARA (1 g/m 2 ) 5/5	mLDAC	CR	Yes	Dead	8.0 mo
	9	FLANG4	mLDAC	CRp	No	Dead	5.2 mo
	10	MTZ (12 mg/m 2 )/ARA(2 g/m 2 ) 3/5	mLDAC	NR	NA	Dead	2.1 mo
	11	MTZ (12 mg/m 2 )/ARA(2 g/m 2 ) 3/5	mLDAC	CR	No	Dead	12.1 mo
	12	MTZ (12 mg/m 2 )/ARA(2 g/m 2 ) 3/5	DAC	CR	No	Alive	16.9 mo
	13	MTZ (12 mg/m 2 )/ARA(2 g/m 2 ) 3/5	mLDAC	CR	No	Alive	16.9 mo

Supplementary